

HervÃ© Tilly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967827/publications.pdf>

Version: 2024-02-01

25
papers

1,334
citations

840776

11
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1583
citing authors

#	ARTICLE	IF	CITATIONS
1	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
2	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	10.7	272
3	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , the, 2019, 6, e254-e265.	4.6	184
4	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	3.5	131
5	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	10.7	101
6	Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 1094-1101.	3.5	97
7	Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. <i>Haematologica</i> , 2015, 100, e280-e284.	3.5	69
8	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	7.7	58
9	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. <i>Haematologica</i> , 2020, 106, 154-162.	3.5	58
10	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
11	EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic. <i>HemaSphere</i> , 2021, 5, e529.	2.7	11
12	Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 1047-1055.	2.2	8
13	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. <i>Journal of Clinical Oncology</i> , 2020, 38, 8053-8053.	1.6	8
14	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. <i>Hematological Oncology</i> , 2022, 40, 505-517.	1.7	7
15	Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 127-135.	2.4	6
16	Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. <i>Haematologica</i> , 2022, 107, 755-758.	3.5	6
17	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1BA-1-1BA-1.	1.4	5
18	Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence. <i>EJNMMI Research</i> , 2021, 11, 37.	2.5	3

#	ARTICLE	IF	CITATIONS
19	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.. Journal of Clinical Oncology, 2021, 39, 7543-7543.	1.6	3
20	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkinâ€™s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.. Journal of Clinical Oncology, 2021, 39, 7544-7544.	1.6	3
21	Response to A+CHP by CD30 expression in the ECHELON-2 trial.. Journal of Clinical Oncology, 2019, 37, 7538-7538.	1.6	3
22	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. Journal of Clinical Oncology, 2019, 37, 7544-7544.	1.6	3
23	Double Hit Lymphoma Diagnosis and Treatment in Europeâ€™”A Crossâ€™Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG). HemaSphere, 2020, 4, e481.	2.7	3
24	Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology, 2022, 40, 7551-7551.	1.6	1
25	Asia subpopulation analysis from the phase III POLARIX trial.. Journal of Clinical Oncology, 2022, 40, 7558-7558.	1.6	0